Today it was reported that the President & CEO of Exelixis (NASDAQ: EXEL), Michael Morrissey, exercised options to sell 234,267 EXEL shares at $1.70 a share, for a total transaction value of $4.93M.
In addition to Michael Morrissey, one other EXEL executive reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Exelixis’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $186 million and quarterly net profit of $87.49 million. In comparison, last year the company earned revenue of $99.01 million and had a net profit of $17.6 million. EXEL’s market cap is $6.26B and the company has a P/E ratio of 20.10. Currently, Exelixis has an average volume of 1.93M.
Based on 6 analyst ratings, the analyst consensus is Strong Buy with an average price target of $33.00, reflecting a -37.3% downside.
The insider sentiment on Exelixis has been negative according to 61 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic.
